Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;111(1):100-105.
doi: 10.1177/03008916241302919. Epub 2024 Dec 15.

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Benedetta Pellegrino  1 , Filippo Giovanardi  2 , Carmelo Tibaldi  3 , Luca Moscetti  4 , Andrea Vingiani  5 , Luana Calabrò  6 , Gabriele Zoppoli  7 , Stefania Didone  5 , Lorenzo Ferrando  7 , Enrico Franceschi  8 , Renata Todeschini  9 , Michele Tognetto  9 , Alessandro Leonetti  1 , Roberta Minari  1 , Chiara Tommasi  1   10 , Olga Serra  10   11 , Luca Boni  12 , Giancarlo Pruneri  5 , Antonino Musolino  11   13
Affiliations

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

Benedetta Pellegrino et al. Tumori. 2025 Feb.

Abstract

The Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) is Italy's first cooperative oncology research group, evolving to conduct academic clinical trials since 1985. With 167 publications and collaborations with national and international partners, GOIRC has significantly impacted clinical practices. The group emphasizes training and has developed robust internal standard operative procedures (SOPs) to enhance data quality. GOIRC is poised to tackle future challenges in translational research, focusing on innovative trial designs, precision medicine, and leveraging different laboratory resources across its 42 units.

Keywords: Breast oncology; gynecologic oncology; molecular oncology.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: BP reports grants from Roche; other support from Pfizer, Lilly, Gilead, and Novartis; and personal fees from Merk. Member of advisory board for Daiichi- Sankyo. AM: Consulting or Advisory Role: Companies: Lilly, Eisai, Seagen, Daiichi Sankyo, Astra Zeneca, Gilead, Pfizer Research Funding: Companies: Lilly, Roche, Seagen, Pfizer Travel, Accommodations, Expenses: Companies: Lilly, Eisai, Daiichi Sankyo, Astra Zeneca, Gilead, Pfizer, Novartis All other authors have declared no conflict of interest.

LinkOut - more resources